![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DYAX ANNOUNCES POSITIVE INTERIM RESULTS FROM EDEMA2 TRIAL OF DX-88 IN HEREDITARY ANGIOEDEMA
DYAX ANNOUNCES POSITIVE INTERIM RESULTS FROM EDEMA2 TRIAL OF DX-88 IN HEREDITARY ANGIOEDEMA
Dyax has announced positive interim results from its Phase II, open-label, dose-ranging, repeat-dosing clinical trial of DX-88 in hereditary angioedema (HAE), referred to as EDEMA2 (Evaluating DX-88's Effects on Mitigating Angioedema).
The interim EDEMA2 results, based on 61 HAE attacks, highlight that DX-88 is well-tolerated and can elicit rapid clinical responses, with a median time to clinical response of 35 minutes.
In addition to the Phase II results, Dyax announced that it plans to initiate a Phase III trial of DX-88 in HAE, referred to as EDEMA3, during the first half of 2005. The company expects EDEMA3 to be a controlled, multicenter, international trial of approximately the same size as its successfully completed 48-patient EDEMA1 trial.
The DX-88 development program for HAE is in a joint venture with Genzyme. Pending a positive outcome of EDEMA3, Dyax expects to file a biologics license application during 2006 for marketing approval of DX-88 for the treatment of HAE in the U.S. The company also intends to file an equivalent marketing authorization application for approval of the drug in Europe.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct